We performed an open, prospective, randomized, three-cell, 6-month clinical trial on the prevention of duodenal ulcer (DU) relapse, comparing three ome-prazole schedules, i.e. 20 mg daily, 20 mg every other day (e.o.d.) and 40 mg on Saturdays and Sundays (S/S). Diagnosis of either healed or relapsed DU was on an endoscopic basis. Follow-up visits were performed at 3-monthly intervals with endoscopy at the baseline, after 6 months and at every symp tomatic relapse. Statistics: χ<sup>2</sup> test with standardized deviates, Yates’ corrected χ<sup>2</sup> test and analysis of variance (one-way). One hundred and fifteen patients were randomized to receive omeprazole 20 mg/day, 123 omeprazole 20 mg e.o.d. and 115 40 mg S/S. Twenty-eight dropped out (11, 8 and 9, respectively). Demonstrated ulcer relapse rates were 5.7% with omeprazole 20 mg/day, 18.1% with 20 mg e.o.d. and 17.6% with 40 mgS/S (p = 0.0124, ‘per-protocol’ analysis). No clinically significant adverse effects were recorded. In conclu sion, of the three schedules studied, omeprazole 20 mg/day proved the most effective maintenance treatment for healed DU. © 1995 S. Karger AG, Basel.

Six months of omeprazole 20 mg daily, 20 mg every other day or 40 mg at weekends in duodenal ulcer patients: A multicenter, prospective, comparative study / Di Mario, F.. - In: DIGESTION. - ISSN 0012-2823. - 56:3(1995), pp. 181-186. [10.1159/000201240]

Six months of omeprazole 20 mg daily, 20 mg every other day or 40 mg at weekends in duodenal ulcer patients: A multicenter, prospective, comparative study

Di Mario, F.
1995

Abstract

We performed an open, prospective, randomized, three-cell, 6-month clinical trial on the prevention of duodenal ulcer (DU) relapse, comparing three ome-prazole schedules, i.e. 20 mg daily, 20 mg every other day (e.o.d.) and 40 mg on Saturdays and Sundays (S/S). Diagnosis of either healed or relapsed DU was on an endoscopic basis. Follow-up visits were performed at 3-monthly intervals with endoscopy at the baseline, after 6 months and at every symp tomatic relapse. Statistics: χ2 test with standardized deviates, Yates’ corrected χ2 test and analysis of variance (one-way). One hundred and fifteen patients were randomized to receive omeprazole 20 mg/day, 123 omeprazole 20 mg e.o.d. and 115 40 mg S/S. Twenty-eight dropped out (11, 8 and 9, respectively). Demonstrated ulcer relapse rates were 5.7% with omeprazole 20 mg/day, 18.1% with 20 mg e.o.d. and 17.6% with 40 mgS/S (p = 0.0124, ‘per-protocol’ analysis). No clinically significant adverse effects were recorded. In conclu sion, of the three schedules studied, omeprazole 20 mg/day proved the most effective maintenance treatment for healed DU. © 1995 S. Karger AG, Basel.
Six months of omeprazole 20 mg daily, 20 mg every other day or 40 mg at weekends in duodenal ulcer patients: A multicenter, prospective, comparative study / Di Mario, F.. - In: DIGESTION. - ISSN 0012-2823. - 56:3(1995), pp. 181-186. [10.1159/000201240]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11381/2844210
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? ND
social impact